Netupitant
 | |
| Systematic (IUPAC) name | |
|---|---|
|
2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| PubChem | CID 6451149 |
| ChemSpider | 4953629 |
| Chemical data | |
| Formula | C30H32F6N4O |
| Molar mass | 578.59 g/mol |
| |
| |
Netupitant is an antiemitic drug. In the United States, the combination drug netupitant/palonosetron (Akynzeo) is approved by the Food and Drug Administration for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.[1]
Mechanism of action
Netupitant is a selective NK1 receptor antagonist.[2]
References
- ↑ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014.
- ↑ Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo G (2012). "In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant". Peptides 37: 86–97. doi:10.1016/j.peptides.2012.06.010.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.